Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report
Annals of Surgical Treatment and Research
; : 216-218, 2018.
Article
em En
| WPRIM
| ID: wpr-713940
Biblioteca responsável:
WPRO
ABSTRACT
Clinical outcomes of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) in patients with multiple myeloma (MM) have not been established in terms of HCC recurrence and MM deterioration after LDLT. A 51-year-old man with chronic hepatitis B was diagnosed with HCC and MM. Since the patient also had decompensated liver cirrhosis (LC), he underwent LDLT prior to autologous peripheral blood stem cell transplantation (PBSCT) to prevent fulminant hepatitis due to HBV reactivation. The patient received Epstein-Barr virus prophylaxis and a triple immunosuppressive regimen of tacrolimus, everolimus, and steroid after LDLT. Autologous PBSCT was performed 7 months after LDLT. He showed a complete response to treatment of MM without post-LT complications or HCC recurrence. In conclusion, LDLT could be adapted for treatment of MM patients with combined HCC and decompensated LC because it is an effective strategy of preventing HBV reactivation and HCC recurrence after induction therapy of MM.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Recidiva
/
Transplante de Fígado
/
Tacrolimo
/
Herpesvirus Humano 4
/
Carcinoma Hepatocelular
/
Doadores Vivos
/
Hepatite B Crônica
/
Transplante de Células-Tronco de Sangue Periférico
/
Everolimo
/
Hepatite
Limite:
Humans
Idioma:
En
Revista:
Annals of Surgical Treatment and Research
Ano de publicação:
2018
Tipo de documento:
Article